Kevin Rocco joined Biorez in February 2014 as the lead engineer, and in November 2016 was promoted to CEO and joined the Board of Directors. As CEO, Kevin has led a $1.5 million fundraising effort, rebranded the company, grown the Biorez team, and filed a new patent for Biorez’s lead ACL technology in March 2017. Prior to joining Biorez, Kevin studied tissue engineering at Yale University, where he coauthored 17 publications in the field and was a part of the research team with the first US clinical study of a bioresorbable vascular graft in human. Kevin began his career as an engineer in new technology development at Covidien (acquired by Medtronic) where he investigated a novel bioresorbable hernia mesh device. He holds a B.S. and M.S. in Biomedical Engineering from The University of Connecticut and Yale University, respectively.